Latest News for Baselode Energy Stock (OTC:BSENF)

Baselode Energy Corp is a uranium exploration company focused on discovering high-grade, basement-hosted, near-surface deposits in Canada's Athabasca Basin. Baselode is led by James Sykes, a uranium geologist who has contributed to the discovery of over 550 million pounds of uranium.

BASELODE ENERGY CORP by BASELODE ENERGY CORP.

Baselode Energy Corp

Lilium N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>), developer of the first all-electric vertical take-off and landing (&quot;eVTOL&quot;) jet and global pioneer in Regional Air Mobility (RAM), today announced it has started construction of an advanced test facility for integration and certification testing of the Lilium Jet. Designed in partnership with global engineering group SEGULA Technologies and located at Lilium&#39;s headquarters near Munich, Germany, the state-of-the-art facility is due to become operational in late Summer 2024.
The test site will house a complete, fully integrated aircraft and be used for testing of the Lilium Jet&#39;s avionics, flight controls, propulsion system and electrical power system. As part of the Lilium Jet&#39;s certification campaign, the facility will be used to simulate flights and verify the performance of the aircraft through multiple flight profiles.

News

LILM

Lilium Begins Construction of Certification Test Facility for the Lilium Jet with SEGULA Technologies

REE Automotive Says P7-C Electric Trucks And Platforms Approved For $30,000 Incentive Per Vehicle In Massachusetts

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) with a Buy and maintains $12 price target.

Price Target

Reiteration

Analyst Ratings

EYEN

HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target

HC Wainwright &amp; Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) with a Buy and lowers the price target from $12 to $11.

BDTX

HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $11

Biotech

General

BIIB

IONS

Ionis And Biogen Say Development Of BIIB105 Will Be Discontinued Based On Data From Phase 1/2 Study

The company anticipates the BLA filing to be completed in the&nbsp;third quarter&nbsp;of 2024 and believe the procedural timelines for review combined with the rolling submission process will allow for approval around mid-2025.

AXGN

Axogen Initiates Rolling Submission Process With FDA For Biologics License Application For Licensure Of Avance Nerve Graft

WIIM

Under Armour shares are trading lower after the company issued weak FY25 guidance.

Guidance

Under Armour Sees FY25 Adj. EPS $0.18-$0.25 vs $0.59 Est., Revenue Down Low-Double-Digit Percentage Rate Including Expected 15-17% Decline In North America

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for&nbsp;$850 million&nbsp;in cash, with potential for an additional milestone payment.
Proteologix&#39;s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma, and PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in preclinical development for moderate to severe AD. Since AD and asthma are both heterogeneous diseases with different disease-driving pathways in distinct patient subpopulations, targeting multiple pathways offers the potential to deliver high-bar efficacy and remission.
PX128 inhibits IL-13-mediated Th2 skin inflammation, an important disease-driving pathway in&shy; AD and asthma, as well as TSLP, a mediator of tissue inflammation in AD and asthma. Like PX128, PX130 inhibits IL-13-mediated Th2 skin inflammation. PX130 also inhibits IL-22 to restore the skin barrier and prevent inflammation from environmental triggers, such as allergens. Both assets are designed for infrequent dosing intervals, which offers convenience patients prefer. Together, these pipeline additions demonstrate a strategic approach to build a portfolio of differentiated and complementary bispecifics.

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment for $850M Cash and Earnout Consideration

AGFY

Nature's Miracle And Agrify Corporation Announces Signing Of The Definitive Merger Agreement

MTNB

Matinas BioPharma Says New In Vitro Data Showing LNC Platform Delivering Small Oligonucleotides Presented At TIDES USA 2024

Baird analyst Jeffrey Meuler maintains Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) with a Outperform and lowers the price target from $20 to $15.

SPIR

Baird Maintains Outperform on Spire Global, Lowers Price Target to $15

Buybacks

Under Armour Announces $500M Share Repurchase Program

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.07 by 57.14 percent. The company reported quarterly sales of $1.330 billion which met the analyst consensus estimate. This is a 4.93 percent decrease over sales of $1.399 billion the same period last year.

Earnings

Earnings Beats

Under Armour Q4 2024 Adj EPS $0.11 Beats $0.07 Estimate, Sales $1.330B Inline

JFBR

Jeffs' Brands' Subsidiary Fort Products Revenues In Amazon Marketplace Rises 55% To $2.125M In Q1

&nbsp;Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) (&quot;Entero&quot; or the &quot;Company&quot;), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today unveiled its new corporate name and website. The rebranding follows the recent business combination with ImmunogenX and reflect the Company&#39;s focus on addressing unmet needs in GI health that include celiac disease, an indication for which there are no approved medicines today. Entero&#39;s common stock will commence trading on May 17, 2024, on the Nasdaq Capital Market under the new ticker symbol of ENTO.

Government

Regulations

ENTO

FWBI

First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease

Multi Ways Holdings FY23 Total Revenue Decrease By 6.1%

Baird analyst William Power maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Outperform and lowers the price target from $65 to $62.

Baird Maintains Outperform on Dynatrace, Lowers Price Target to $62

Baird analyst David Koning maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Neutral and lowers the price target from $372 to $345.

Baird Maintains Neutral on Accenture, Lowers Price Target to $345

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) with a Buy and maintains $4.25 price target.

Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target

Baselode Energy Corporation (TSE:FIND) has released an update. Baselode Energy Corp. is set to expand their drill program at the Catharsis uranium ...

Baselode Expands Uranium Drilling Efforts at Catharsis

Baselode Energy Corporation (TSE:FIND) has released an update. Baselode Energy Corp. is gearing up to start a promising 1,500-metre drill program a...

Baselode Energy Advances Uranium Drilling Projects

Baselode Energy Corporation (TSE:FIND) has released an update. Baselode Energy Corp. has initiated a significant drilling program at Bear, targetin...

Baselode Energy Launches Uranium Drilling Venture

BSENF

Press Releases

Baselode Details Drill Program Strategy for the Hook Project

BTV Showcases: Northstar Gaming, Goldshore Resources, Nighthawk Gold, Baselode Energy & Marimaca Copper

Baselode Energy Corp. to Present at the Clean Energy and Precious Metals Virtual Investor Conference on December 4th

Baselode Energy latest drill results show discovery of new Uranium anomalies East of ACKIO prospect

Baselode Energy CEO discusses Catharsis exploration and Athabasca 2.0 strategy - PDAC 2024

Baselode Energy begins 1500 metre drill program at Bear Uranium project in Athabasca Basin

Small Cap

Opinion

Investment Banks & Hedge Funds Stepping Up Activity in Physical Uranium as Prices Spike

Fintech

Commodities

Baselode Energy Initiates Drill Program and Geophysical Survey in Athabasca Basin